Physician profile
Fred G Hamaty
NPI 1023058567
$14,900.46
in general payments reported to CMS, 2019-2025
34 companies · $3,032 in 2025
The $3,032 reported for 2025 was more than what 84% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,015 · 2020: $922 · 2021: $1,915 · 2022: $2,193 · 2023: $2,688 · 2024: $3,135 · 2025: $3,032.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,845 · Education: $9.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,845.48 |
| Education | $9.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,516.95 | 2019-2025 | |
| Pfizer INC. | $1,385.15 | 2019-2025 | |
| Galderma Laboratories, L.P. | $1,302.74 | 2019-2025 | Nemluvio, Epsolay, Aklief |
| Amgen INC. | $1,195.14 | 2020-2025 | Otezla, Otezla |
| Genzyme Corporation | $885.36 | 2019-2025 | |
| Incyte Corporation | $841.22 | 2021-2025 | Opzelura |
| Leo Pharma INC. | $831.93 | 2019-2025 | Adbry, Anzupgo |
| Journey Medical Corporation | $815.48 | 2019-2025 | |
| Janssen Biotech, INC. | $725.72 | 2019-2025 | Simponi Aria, Stelara, Simponi |
| Regeneron Healthcare Solutions, INC. | $640.72 | 2019-2025 | Dupixent, Libtayo |
| Arcutis Biotherapeutics, INC. | $615.91 | 2023-2025 | Zoryve |
| E.R. Squibb & Sons, L.L.C. | $597.47 | 2022-2024 | Sotyktu |
| Novartis Pharmaceuticals Corporation | $573.59 | 2020-2025 | |
| Ucb, INC. | $546.73 | 2021-2025 | Bimzelx, Cimzia |
| Sun Pharmaceutical Industries INC. | $522.99 | 2019-2025 | Winlevi, Ilumya |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $474.75 | 2020-2024 | Olumiant, Taltz |
| Vyne Pharmaceuticals INC. | $256.10 | 2020-2021 | |
| Dermavant Sciences, INC. | $234.31 | 2022-2024 | Vtama |
| Mayne Pharma Commercial LLC | $212.48 | 2019-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $131.72 | 2019-2021 | |
| Biocon Biologics INC | $90.24 | 2024-2025 | Yesintek, Hulio |
| Sandoz INC. | $81.39 | 2019-2021 | |
| Almirall LLC | $80.76 | 2019-2020 | |
| Epi Health, LLC | $49.61 | 2021-2022 | |
| Celgene Corporation | $49.54 | 2019 | |
| Biofrontera INC. | $49.27 | 2021-2024 | Xepi, Bf-Rhodoled, Ameluz |
| Prugen, INC. Pharmaceuticals | $46.41 | 2019 | |
| Blueprint Medicines Corporation | $29.99 | 2023 | |
| Dermira, INC. | $24.93 | 2021 | |
| Aclaris Therapeutics, INC. | $23.16 | 2019 | |
| Kyowa Kirin, INC. | $21.50 | 2019 | |
| Verrica Pharmaceuticals INC. | $17.73 | 2023 | Ycanth |
| Lexicon Pharmaceuticals, INC. | $16.99 | 2024 | |
| Mission Pharmacal Company | $12.48 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fred Hamaty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.